Mkt Cap$2.17T+2.22%
24h Vol$85.42B
BTC Dom55.6%
ETH Dom9.0%
F&G12Extreme Fear
BTC$60,312.00+2.08% ETH$1,613.22+3.41% USDT$0.9986+0.00% BNB$560.05+2.26% USDC$0.99970.00% XRP$1.06+1.91% SOL$75.18+6.67% TRX$0.3213-0.18% FIGR_HELOC$1.05+2.60% HYPE$66.74+9.75% DOGE$0.0735+1.16% RAIN$0.0159+2.62% USDS$0.9996+0.01% LEO$9.56+1.43% ZEC$407.48+10.28% XLM$0.1754+2.78% BTC$60,312.00+2.08% ETH$1,613.22+3.41% USDT$0.9986+0.00% BNB$560.05+2.26% USDC$0.99970.00% XRP$1.06+1.91% SOL$75.18+6.67% TRX$0.3213-0.18% FIGR_HELOC$1.05+2.60% HYPE$66.74+9.75% DOGE$0.0735+1.16% RAIN$0.0159+2.62% USDS$0.9996+0.01% LEO$9.56+1.43% ZEC$407.48+10.28% XLM$0.1754+2.78%
News

market analysis

Total Stories
1,145
Section
market analysis
Merck's Stock Rises Amid New Cancer Treatment Drug Breakthrough
Market Analysis

Merck’s Stock Rises Amid New Cancer Treatment Drug Breakthrough

MSD's new injectable Keytruda formulation offers similar effectiveness to the intravenous version, potentially halving treatment time.

Tim FriesMar 28, 20253 min read